Outcomes for Intravesical Abobotulinumtoxin A (Dysport) Treatment in the Active Management of Overactive Bladder Symptoms—A Prospective Study
Authors:
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Botulinum toxin type A for the treatment of non‐neurogenic overactive bladder: does using onabotulinumtoxin A ( B otox ® ) or abobotulinumtoxin A ( D ysport ® ) make a difference?BJU International, 2013
- Treatment of Neurogenic Detrusor Overactivity with Botulinum Toxin A: The First Seven YearsUrologia Internationalis, 2009
- Outcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive BladderJournal of Urology, 2009
- What a Patient With Refractory Idiopathic Detrusor Overactivity Should Know About Botulinum Neurotoxin Type A InjectionJournal of Urology, 2009
- Discontinuation Rates of Anticholinergic Medications Used for the Treatment of Lower Urinary Tract SymptomsObstetrics & Gynecology, 2008
- Refractory Idiopathic Urge Urinary Incontinence and Botulinum A InjectionJournal of Urology, 2008
- The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well‐being in men and women: results from the EPIC studyBJU International, 2008
- Success of Repeat Detrusor Injections of Botulinum A Toxin in Patients with Severe Neurogenic Detrusor Overactivity and IncontinenceEuropean Urology, 2005
- The Impact of Urinary Urgency and Frequency on Health-Related Quality of Life in Overactive Bladder: Results from a National Community SurveyValue in Health, 2004
- The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence SocietyNeurourology and Urodynamics, 2002